IP Library Granted Patent US 7,507,824
Granted Patent B2
US 7,507,824 · App. 10/637,681 · Granted Mar 24, 2009

Spiro(2H-1benzopyran-2,4′-piperidine) derivates as glycine transport inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,507,824
App. No.
10/637,681
Granted
Mar 24, 2009
Kind
B2
Abstract

The present invention relates to spiro[2H-1-benzopyran-2,4′-piperidine] derivatives having general formula (I), or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these spiro[2H-1-benzopyran-2,4′-piperidine] derivatives in therapy, more specifically for the treatment of CNS disorders.

Claims (12)

1. A spiro[2H-1-benzopyran-2,4′-piperidine] derivative having formula I:

wherein the dotted line represents an optional bond;

Y represents 1-2 substituents independently selected from hydrogen, halogen, (C 1-6 )alkyl optionally substituted with one or more halogens, (C 1-6 )alkyloxy optionally substituted with one or more halogens, (C 2-6 )alkenyloxy, (C 2-6 )alkynyloxy, pyridinylmethyloxy, SR 3 , NR 3 R 4 , OSO 2 R 5 , and NR 3 SO 2 R 4 ; or 2 substituents Y may together form O—(CH 2 ) n —O or O—(CF 2 ) n —O, where n is 1 or 2;

X represents 1-3 substituents independently selected from hydrogen, halogen, hydroxy, (C 1-4 )alkyloxy, SR 3 , NR 3 SO 2 R 4 and (C 1-4 )alkyl, optionally substituted with halogen;

R 1 is hydrogen, (C 1-4 )alkyl or (C 6-12 )aryl;

R 2 , R 3 and R 4 are independently hydrogen or (C 1-4 ) alkyl;

R 5 is (C 1-4 )alkyl (optionally substituted with one or more halogens) or (C 6-12 )aryl (optionally substituted with (C 1-4 )alkyl); or a pharmaceutically acceptable salt thereof,

wherein at least one of Y represents 1 substituent selected from pyridinylmethyloxy; or at least 2 substituents Y together form O—(CH 2 ) n —O or O—(CF 2 ) n —O, where n is 1 or 2.

2. The spiro[2H-1-benzopyran-2,4′-piperidine] derivative according to claim 1 , wherein the dotted line represents a bond.

3. The spiro[2H-1-benzopyran-2,4′-piperidine] of claim 1 , wherein R 1 and R 2 are hydrogen.

4. The spiro[2H-1-benzopyran-2,4′-piperidine] of claim 1 , wherein Y represents is pyridinylmethyloxy.

5. A pharmaceutical composition, comprising: a spiro[2H-1-benzopyran-2,4′-piperidine] according to claim 1 , or a pharmaceutically acceptable salt thereof, in admixture with pharmaceutically acceptable auxiliaries.

Assignments (5)
MERGER Recorded Mar 8, 2013
From: ORGANON BIOSCIENCES NEDERLAND B.V.
To: MERCK SHARP & DOHME B.V.
Reel/Frame 029940/0296 →
MERGER Recorded Mar 7, 2013
From: MSD OSS B.V.
To: ORGANON BIOSCIENCES NEDERLAND B.V.
Reel/Frame 029939/0001 →
MERGER Recorded Dec 1, 2011
From: N.V. ORGANON
To: MSD OSS B.V.
Reel/Frame 027307/0482 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2007
From: AKZO NOBEL N.V.
To: N.V. ORGANON
Reel/Frame 018816/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2003
From: GIBSON, SAMUEL GEORGE; MILLER, DAVID JOHN
To: AKZO NOBEL N.V.
Reel/Frame 014386/0107 →